

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) EP 0 952 221 A2

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:

27.10.1999 Bulletin 1999/43

(51) Int Cl. 6: C12N 15/53, C12N 15/60,

C12N 1/21, C12N 1/20,

C12P 13/14

// (C12N1/20, C12R1:01, 1:425)

(21) Application number: 99105508.8

(22) Date of filing: 17.03.1999

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 18.03.1998 JP 6906898

19.10.1998 JP 29712998

(71) Applicant: Ajinomoto Co., Ltd.

Tokyo (JP)

(72) Inventors:

• Izui, Hiroshi c/o Ajinomoto Co., Inc.

Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)

• Ono, Eiji c/o Ajinomoto Co., Inc.  
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)

• Matsui, Kazuhiko c/o Ajinomoto Co., Inc.  
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)

• Moriya, Mika c/o Ajinomoto Co., Inc.  
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)

• Ito, Hisao c/o Ajinomoto Co., Inc.  
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)

• Hara, Yoshihiko c/o Ajinomoto Co., Inc.  
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)

(74) Representative: Strehl Schübel-Hopf & Partner  
Maximilianstrasse 54

80538 München (DE)

### (54) L-glutamic acid-producing bacterium and method for producing L-glutamic acid

(57) L-Glutamic acid is produced by culturing in a liquid culture medium a microorganism belonging to the genus *Enterobacter* or *Serratia* and having an ability to produce L-glutamic acid, which increases in an activity of enzyme catalyzing a reaction for L-glutamic acid bio-

synthesis, or which decreases in or is deficient in an activity of an enzyme catalyzing a reaction branching from a pathway for L-glutamic acid biosynthesis and producing a compound other than L-glutamic acid, and collecting produced L-glutamic acid from the culture medium.

**Description****BACKGROUND OF THE INVENTION**

5 [0001] The present invention relates to a novel L-glutamic acid-producing bacterium and a method for producing L-glutamic acid by fermentation using the same. L-Glutamic acid is an important amino acid as food, drugs and the like.

[0002] L-Glutamic acid has conventionally been produced by fermentation methods utilizing the so-called coryneform L-glutamic acid-producing bacteria which principally belong to the genera *Brevibacterium*, *Corynebacterium*, and *Microbacterium* or variants thereof ("Amino Acid Fermentation", Gakkai Shuppan Center, pp.195-215, 1986). As methods 10 for producing L-glutamic acid by fermentation utilizing other bacterial strains, there have been known the methods utilizing microorganisms of the genera *Bacillus*, *Streptomyces*, *Penicillium* and the like (United States Patent No. 3,220,929), the methods utilizing microorganisms of the genera *Pseudomonas*, *Arthrobacter*, *Serratia*, *Candida* and the like (United States Patent No. 3,563,857), the methods utilizing microorganisms of the genera *Bacillus*, *Pseudomonas*, *Serratia* and the like or *Aerobacter aerogenes* (currently referred to as *Enterobacter aerogenes*) (Japanese 15 Patent Publication (KOKOKU) No. 32-9393(1957)), the method utilizing variant strains of *Escherichia coli* (Japanese Patent Application Laid-Open (KOKAI) No. 5-244970(1993)) and the like.

[0003] Though the productivity of L-glutamic acid has considerably been improved by breeding of such microorganisms as mentioned above or improvements of production methods, it is still desired to develop a more inexpensive and more efficient method for producing L-glutamic acid in order to meet the expected markedly increasing future demand 20 of the amino acid.

**SUMMARY OF THE INVENTION**

25 [0004] The object of the present invention is to find a novel L-glutamic acid-producing bacterium having a high ability to produce L-glutamic acid, thereby developing a more inexpensive and more efficient method for producing L-glutamic acid.

[0005] To achieve the aforementioned object, the present inventors intensively searched for and studied microorganisms having the ability to produce L-glutamic acid that are different from the previously reported microorganisms. As a result, they found that certain strains derived from microorganisms belonging to the genus *Enterobacter* or *Serratia* 30 had a high ability to produce L-glutamic acid, and have completed the present invention.

[0006] Thus, the present invention provide:

(1) a microorganism belonging to the genus *Enterobacter* or *Serratia* and having an ability to produce L-glutamic acid and at least one of the following properties:

35 (a) the microorganism increases in an activity of an enzyme catalyzing a reaction for L-glutamic acid biosynthesis; and  
 (b) the microorganism decreases in or is deficient in an activity of an enzyme catalyzing a reaction branching from a pathway for L-glutamic acid biosynthesis and producing a compound other than L-glutamic acid;

40 (2) a microorganism of the above (1) wherein the enzyme catalyzing the reaction for the L-glutamic acid biosynthesis is at least one selected from the group consisting of citrate synthase (abbreviated as "CS" hereinafter), phosphoenolpyruvate carboxylase (abbreviated as "PEPC" hereinafter), and glutamate dehydrogenase (abbreviated as "GDH" hereinafter);

45 (3) a microorganism of the above (2) wherein the enzyme catalyzing the reaction for the L-glutamic acid biosynthesis includes all of CS, PEPC and GDH;

(4) a microorganism of any one of the above (1) to (3) wherein the enzyme catalyzing the reaction branching from the pathway for L-glutamic acid biosynthesis and producing the compound other than L-glutamic acid is  $\alpha$ -ketoglutarate dehydrogenase (abbreviated as "aKGDH" hereinafter);

50 (5) a microorganism of any one of the above (1) to (4) which is *Enterobacter agglomerans* or *Serratia liquefacience*; and

(6) a method for producing L-glutamic acid which comprises culturing the microorganism as defined in any one of the above (1) to (5) in a liquid culture medium to produce and accumulate L-glutamic acid in the culture medium, and collecting the L-glutamic acid from the culture medium.

55 [0007] Because the microorganism of the present invention have a high ability to produce L-glutamic acid, it is considered to be possible to impart a further higher production ability to the microorganism by using the breeding techniques previously known for the coryneform L-glutamic acid-producing bacteria and the like, and it is expected to contribute

EP 0 952 221 A2

to development of a more inexpensive and more efficient method for producing L-glutamic acid by appropriately selecting culture conditions and the like.

BRIEF EXPLANATION OF THE DRAWINGS

- 5 [0008] Figure 1 shows construction of a plasmid pMWCPG having a *gltA* gene, a *ppc* gene and a *gdhA* gene.
- [0009] Figure 2 shows construction of a plasmid pSTVG having the *gdhA* gene.
- [0010] Figure 3 shows construction of a plasmid RSF-Tet having a replication origin of a wide-host-range plasmid RSF1010 and a tetracycline resistance gene.
- 10 [0011] Figure 4 shows construction of a plasmid RSFCPG having the replication origin of the wide-host-range plasmid RSF1010, the tetracycline resistance gene, the *gltA* gene, the *ppc* gene and the *gdhA* gene.
- [0012] Figure 5 shows construction of a plasmid pMWCB having the *gltA* gene.
- [0013] Figure 6 shows a restriction map of a DNA fragment of pTWVEK101 derived from *Enterobacter agglomerans*.
- 15 [0014] Figure 7 shows comparison of an amino acid sequence deduced from a nucleotide sequence of a *sucA* gene derived from *Enterobacter agglomerans* with one derived from *Escherichia coli*. The upper sections: *Enterobacter agglomerans*, the lower sections: *Escherichia coli* (the same shall apply hereinafter).
- [0015] Figure 8 shows comparison of an amino acid sequence deduced from a nucleotide sequence of a *sucB* gene derived from *Enterobacter agglomerans* with one derived from *Escherichia coli*.
- 20 [0016] Figure 9 shows comparison of an amino acid sequence deduced from a nucleotide sequence of a *sdhB* gene derived from *Enterobacter agglomerans* with one derived from *Escherichia coli*.
- [0017] Figure 10 shows comparison of an amino acid sequence deduced from a nucleotide sequence of a *sucC* gene derived from *Enterobacter agglomerans* with one derived from *Escherichia coli*.

DETAILED DESCRIPTION OF THE INVENTION

- 25 [0018] The present invention will be explained in detail hereinafter.
- [0019] The microorganism of the present invention is a microorganism belonging to the genus *Enterobacter* or *Serratia*, and having at least one of the following properties:
- 30 (a) the microorganism increases in an activity of an enzyme catalyzing a reaction for L-glutamic acid biosynthesis; and  
(b) the microorganism decreases in or is deficient in an activity of an enzyme catalyzing a reaction branching from a pathway for L-glutamic acid biosynthesis and producing a compound other than L-glutamic acid.
- 35 [0020] Such a microorganism can be obtained by using a microorganism belonging to the genus *Enterobacter* or the genus *Serratia* as a parent strain, and imparting the properties of the above (a) and/or (b) to the microorganism. Examples of the microorganism belonging to the genus *Enterobacter* or the genus *Serratia* that can be used as the parent strain are listed below:
- 40 *Enterobacter agglomerans*  
*Enterobacter aerogenes*  
*Enterobacter amnigenus*  
*Enterobacter asburiae*  
*Enterobacter cloacae*  
45 *Enterobacter dissolvens*  
*Enterobacter gergoviae*  
*Enterobacter hormaechei*  
*Enterobacter intermedius*  
*Enterobacter nimipressuralis*  
50 *Enterobacter sakazakii*  
*Enterobacter taylorae*  
*Serratia liquefacience*  
*Serratia entomophila*  
*Serratia ficaria*  
55 *Serratia fonticola*  
*Serratia grimesii*  
*Serratia proteamaculans*  
*Serratia odorifera*

*Serratia plymuthica*  
*Serratia rubidaea*

[0021] More preferably, those bacterial strains listed below can be mentioned:

5      *Enterobacter agglomerans* ATCC 12287  
Enterobacter agglomerans AJ13355  
*Serratia liquefacience* ATCC 14460

10     [0022] The *Enterobacter agglomerans* AJ13355 was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry on February 19, 1998, and received an accession number of FERM P-16644, and then transferred to an international deposition under the Budapest Treaty on January 11, 1999, and received an accession number of FERM BP-6614. The *Enterobacter agglomerans* ATCC 12287, and the *Serratia liquefacience* ATCC 14460 are available from ATCC.

15     [0023] The *Enterobacter agglomerans* AJ13355 is a strain isolated from soil in Iwata-shi, Shizuoka, Japan.

[0024] Physiological properties of AJ13355 are as follows:

- (1) Gram stain: Negative  
(2) Behavior for oxygen: Facultative anaerobe  
20     (3) Catalase: Negative  
(4) Oxidase: Positive  
(5) Nitrate reduction: Negative  
(6) Voges-Proskauer reaction: Positive  
(7) Methyl Red test: Negative  
25     (8) Urease: Negative  
(9) Indole production: Positive  
(10) Motility: Present  
(11) Hydrogen sulfide production in TSI culture medium: Slightly active  
(12)  $\beta$ -Galactosidase: Positive  
30     (13) Sugar assimilability:

Arabinose: Positive  
Sucrose: Positive  
Lactose: Positive  
35     Xylose: Positive  
Sorbitol: Positive  
Inositol: Positive  
Trehalose: Positive  
Maltose: Positive  
40     Melibiose: Positive  
Adonitol: Negative  
Raffinose: Positive  
Salicin: Negative  
Melibiose: Positive

- 45     (14) Glycerose assimilability: Positive  
(15) Organic acid assimilability:

50     Citric acid: Positive  
Tartaric acid: Negative  
Gluconic acid: Positive  
Acetic acid: Positive  
Malonic acid: Negative

55     (16) Arginine dehydrolase: Negative  
(17) Ornithine decarboxylase: Negative  
(18) Lysine decarboxylase: Negative  
(19) Phenylalanine deaminase: Negative

(20) Pigment formation: Yellow

(21) Gelatin liquefaction: Positive

(22) Growth pH: Not good growth at pH 4, good growth at pH 4.5 to 7

5 (23) Growth temperature: Good growth at 25°C, good growth at 30°C, good growth at 37°C, growth possible at 42°C, no growth at 45°C

[0025] From these bacteriological properties, AJ13355 is determined to be *Enterobacter agglomerans*.

[0026] In the working examples described hereinafter, *Enterobacter agglomerans* ATCC12287, *Enterobacter agglomerans* AJ13355, and *Serratia liquefacience* ATCC14460 were used as starting parent strains for obtaining strains which increase in the activity of the enzyme catalyzing the reactions for the L-glutamic acid biosynthesis, or strains which decrease in or are deficient in the activity of the enzyme catalyzing the reaction branching from the pathway for L-glutamic acid biosynthesis and producing the compound other than L-glutamic acid. However, the sugar metabolism by any of bacteria belonging to the genera *Enterobacter* and *Serratia* is achieved via the Embden-Meyerhof pathway, and pyruvate produced in the pathway is oxidized in the tricarboxylic acid cycle under aerobic conditions. L-Glutamic acid is biosynthesized from  $\alpha$ -ketoglutaric acid which is an intermediate of the tricarboxylic acid cycle by GDH or glutamine synthetase/glutamate synthase. Thus, these microorganisms share the same biosynthetic pathway for L-glutamic acid, and microorganism belonging to the genera *Enterobacter* and *Serratia* are encompassed within a single concept according to the present invention. Therefore, microorganisms belonging to the genera *Enterobacter* and *Serratia* other than species and strains specifically mentioned above also fall within the scope of the present invention.

[0027] The microorganism of the present invention is a microorganism belonging to the genus *Enterobacter* or the genus *Serratia* and having an ability to produce L-glutamic acid. The expression "having an ability to produce L-glutamic acid" as herein used means to have an ability to accumulate L-glutamic acid in a culture medium during cultivation. According to the present invention, the ability to produce L-glutamic acid is imparted by giving either one or both of the following characteristics:

25 (a) the microorganism increases in the activity of the enzyme catalyzing the reaction for the L-glutamic acid biosynthesis; and  
 (b) the microorganism decreases in or is deficient in the activity of the enzyme catalyzing the reaction branching from the pathway for L-glutamic acid biosynthesis and producing the compound other than L-glutamic acid.

[0028] As examples of the enzyme catalyzing the reaction for L-glutamic acid biosynthesis of microorganisms of the genus *Enterobacter* or *Serratia*, there can be mentioned GDH, glutamine synthetase, glutamate synthase, isocitrate dehydrogenase, aconitate hydratase, CS, PEPC, pyruvate dehydrogenase, pyruvate kinase, enolase, phosphoglyceromutase, phosphoglycerate kinase, glyceraldehyde-3-phosphate dehydrogenase, triosephosphate isomerase, fructose bisphosphate aldolase, phosphofructokinase, glucose phosphate isomerase and the like. Among these enzymes, one or two or three kinds of CS, PEPC and GDH are preferred. As for the microorganism of the present invention, it is further preferred that activities of all of the three kinds of enzymes, CS, PEPC and GDH, are increased. Whether a microorganism increases in an activity of a target enzyme, and degree of the increase of the activity can be determined by measuring the enzyme activity of a bacterial cell extract or a purified fraction, and comparing it with that of a wild type strain or a parent strain.

[0029] The microorganism of the present invention, which belongs to the genus *Enterobacter* or *Serratia*, and increases in the activity of the enzyme catalyzing the reaction for L-glutamic acid biosynthesis, can be obtained as, for example, a variant where mutation has been made in a gene encoding the enzyme or a genetic recombinant strain by using any of the microorganisms mentioned above as a starting parent strain.

[0030] To enhance the activity of CS, PEPC or GDH, for example, a gene encoding CS, PEPC or GDH can be cloned in a suitable plasmid, and the aforementioned starting parent strain as a host can be transformed with the resulting plasmid. This can increase the copy number of each of the genes encoding CS, PEPC and GDH (hereinafter abbreviated as "gltA gene", "ppc gene", and "gdhA gene", respectively), and as a result the activities of CS, PEPC and GDH can be increased.

[0031] One or two or three kinds selected from the cloned gltA gene, ppc gene and gdhA gene in any combination are introduced into the starting parent strain mentioned above. When two or three kinds of the genes are introduced, either the two or three kinds of the genes are cloned in one kind of plasmid, and introduced into the host, or they are separately cloned in two or three kinds of plasmids that can exist in the same host, and introduced into the host.

[0032] The plasmid is not particularly limited so long as it can autonomously replicate in a microorganism belonging to the genus *Enterobacter* or *Serratia*. Examples of the plasmid include, for example, pUC19, pUC18, pBR322, pHSG299, pHSG298, pHSG399, pHSG398, RSF1010, pMW119, pMW118, pMW219, pMW218 and the like. Other than these plasmids, phage DNA vectors can also be utilized.

[0033] Transformation can be achieved by, for example, the method of D.M. Morrison (Methods in Enzymology 68,

326 (1979)), the method by increasing permeability of recipient cells for DNA with calcium chloride (Mandel, M. and Higa, A., *J. Mol. Biol.*, 53, 159 (1970)), or the like.

[0034] The activities of CS, PEPC and GDH can also be increased by using multiple copies of the *gltA* gene, the *ppc* gene and/or the *gdhA* gene present on the chromosome DNA of the starting parent strain as a host. In order to introduce multiple copies of the *gltA* gene, the *ppc* gene and/or the *gdhA* gene into a chromosome DNA of a microorganism belonging to the genus *Enterobacter* or *Serratia*, sequences present on chromosome DNA in a multiple copy number such as repetitive DNA, and inverted repeats present at an end of transposition factors can be utilized. Alternatively, multiple copies of the genes can also be introduced into a chromosome DNA by utilizing transposition of transposons carrying the *gltA* gene, the *ppc* gene, or the *gdhA* gene. These techniques can increase the copy number 10 of the *gltA* gene, the *ppc* gene, and the *gdhA* gene in transformant cells, and as a result increase the activities of CS, PEPC and GDH.

[0035] Any organisms can be used as a source of the *gltA* gene, the *ppc* gene and the *gdhA* gene used for increasing copy numbers, so long as the organisms have the CS, PEPC and GDH activities. Among such organisms, bacteria, i. e., prokaryotes, such as those bacteria belonging to the genera *Enterobacter*, *Klebsiella*, *Erwinia*, *Pantoea*, *Serratia*, *Escherichia*, *Corynebacterium*, *Brevibacterium*, and *Bacillus* are preferred. As a specific example, *Escherichia coli* can be mentioned. The *gltA* gene, the *ppc* gene and the *gdhA* gene can be obtained from a chromosome DNA of such microorganisms as mentioned above.

[0036] The *gltA* gene, the *ppc* gene and the *gdhA* gene can each be obtained from a chromosome DNA of any of the aforementioned microorganisms by isolating a DNA fragment complementing auxotrophy of a variant strain lacking the CS, PEPC or GDH activity. Alternatively, because the nucleotide sequences of these genes of bacteria of the genus *Escherichia* or *Corynebacterium* have already been elucidated (*Biochemistry*, Vol. 22, pp.5243-5249, 1983; *J. Biochem.* Vol. 95, pp.909-916, 1984; *Gene*, Vol. 27, pp.193-199, 1984; *Microbiology*, Vol. 140, pp.1817-1828, 1994; *Mol. Gen. Genet.* Vol. 218, pp.330-339, 1989; and *Molecular Microbiology*, Vol. 6, pp.317-326, 1992), the genes can be obtained by PCR using primers synthesized based on each of the elucidated nucleotide sequences, and the chromosome DNA 25 as a template.

[0037] The activity of CS, PEPC or GDH can also be increased by, other than by the gene amplification mentioned above, enhancing expression of the *gltA* gene, the *ppc* gene or the *gdhA* gene. For example, the expression is enhanced by replacing the promoter of the *gltA* gene, the *ppc* gene, or the *gdhA* gene with another stronger promoter. Examples of such a strong promoter include, for example, a *lac* promoter, a *trp* promoter, a *trc* promoter, a *tac* promoter, a  $P_R$  promoter and a  $P_L$  promoter of lambda phage and the like. The *gltA* gene, the *ppc* gene, or the *gdhA* gene of which promoter has been substituted is cloned into a plasmid and introduced into a host microorganism, or introduced into a chromosome DNA of host microorganism using a repetitive DNA, inverted repeat, transposon or the like.

[0038] The activities of CS, PEPC or GDH can also be increased by replacing the promoter of the *gltA* gene, the *ppc* gene, or the *gdhA* gene on a chromosome with another stronger promoter (see WO87/03006, and Japanese Patent Application Laid-Open (KOKAI) No. 61-268183(1986)), or inserting a strong promoter at the upstream of each coding sequence of the genes (see *Gene*, 29, pp. 231-241, 1984). Specifically, these are achieved by homologous recombination between the *gltA* gene, the *ppc* gene, or the *gdhA* gene of which promoter is replaced with a stronger promoter or DNA containing a part of them, and a corresponding gene on the chromosome.

[0039] Specific examples of the microorganism belonging to the genus *Enterobacter* or *Serratia* of which CS, PEPC or GDH activity is increased include, for example, *Enterobacter agglomerans* ATCC12287/RSFCPG, *Enterobacter agglomerans* AJ13355/RSFCPG, and *Serratia liquefacience* ATCC14460/RSFCPG.

[0040] Examples of the enzyme catalyzing the reaction branching from the pathway of L-glutamic acid biosynthesis and producing the compound other than L-glutamic acid include, for example,  $\alpha$ KGDH, isocitrate lyase, phosphate acetyltransferase, acetate kinase, acetohydroxy acid synthase, acetolactate synthase, formate acetyltransferase, lactate dehydrogenase, glutamate decarboxylase, 1-pyrroline dehydrogenase and the like. Among these enzymes,  $\alpha$ KGDH is preferred.

[0041] In order to obtain such decrease or deficiency of enzyme activity as mentioned above in a microorganism belonging to the genus *Enterobacter* or *Serratia*, a mutation causing the decrease or deficiency of the enzyme activity can be introduced into a gene encoding the enzyme by a conventional mutagenesis technique or genetic engineering technique.

[0042] Examples of the mutagenesis technique include, for example, the method utilizing irradiation of X-ray or ultraviolet light, the method utilizing treatment with a mutagenic agent such as N-methyl-N'-nitro-N-nitrosoguanidine and the like. The site of gene to which a mutation is introduced may be a coding region encoding an enzyme protein, or an expression regulatory region such as a promoter.

[0043] Examples of the genetic engineering technique include, for example, genetic recombination, genetic transduction, cell fusion and the like. For example, a drug resistance gene is inserted into a target gene to produce a functionally inactivated gene (defective gene). Then, this defective gene is introduced into a cell of a microorganism belonging to the genus *Enterobacter* or *Serratia*, and the target gene on a chromosome is replaced with the defectiv

gene by homologous recombination (gene disruption).

[0044] Whether a microorganism decreases in an activity of a target enzyme or is deficient in the activity, and degree of the decrease of the activity can be determined by measuring the enzyme activity of a bacterial cell extract or a purified fraction of a candidate strain, and comparing it with that of a wild type strain or a parent strain. The  $\alpha$ KGDH enzymatic activity can be measured by, for example, the method of Reed et al. (L.J. Reed and B.B. Mukherjee, Methods in Enzymology 1969, 13, p.55-61).

[0045] Depending on the target enzyme, a target variant can be selected based on a phenotype of the variant. For example, a variant which is deficient in the  $\alpha$ KGDH activity or decreases in the activity cannot grow on a minimal medium containing glucose, or a minimal medium containing acetic acid or L-glutamic acid as an exclusive carbon source, or shows markedly reduced growth rate therein under aerobic conditions. However, even under the same condition, it can exhibit normal growth by addition of succinic acid or lysine, methionine and diaminopimelate to the minimal medium containing glucose. Based on these phenomena, a variant that is deficient in the  $\alpha$ KGDH activity or decreases in the activity can be selected.

[0046] A method for producing a *Brevibacterium lactofermentum* strain lacking the  $\alpha$ KGDH gene based on homologous recombination is detailed in WO95/34672, and a similar method can be used for microorganisms belonging to the genera *Enterobacter* and *Serratia*.

[0047] In addition, procedures of genetic cloning, cleavage and ligation of DNA, transformation and the like are detailed in Molecular Cloning, 2nd edition, Cold Spring Harbor Press (1989) and the like.

[0048] An example of the variant strain that is deficient in the  $\alpha$ KGDH activity or decreases in the activity obtained as described above is *Enterobacter agglomerans* AJ13356. The *Enterobacter agglomerans* AJ13356 was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry on February 19, 1998, received an accession number of FERM P-16645, and then transferred to an international deposition under the Budapest Treaty on January 11, 1999, and received an accession number of FERM BP-6615.

[0049] The microorganism belonging to the genus *Enterobacter* or *Serratia*, and having at least one of the properties (a) and (b) and an ability to produce L-glutamic acid can be cultured in a liquid medium to produce and accumulate L-glutamic acid in the medium.

[0050] The culture medium may be an ordinary nutrient medium containing a carbon source, a nitrogen source, and inorganic salts, as well as organic trace nutrients such as amino acids, vitamins and the like, as required. It can be a synthetic medium or a natural medium. Any carbon sources and nitrogen sources can be used for the culture medium so long as they can be utilized by the microorganism to be cultured.

[0051] The carbon source may be a saccharide such as glucose, glycerol, fructose, sucrose, maltose, mannose, galactose, starch hydrolysates, molasses and the like. Further, an organic acid such as acetic acid and citric acid may also be used alone or in combination with other carbon sources.

[0052] The nitrogen source may be ammonia, ammonium salts such as ammonium sulfate, ammonium carbonate, ammonium chloride, ammonium phosphate, and ammonium acetate, nitrates and the like.

[0053] As organic trace nutrients, amino acids, vitamins, fatty acids, nucleic acids, materials containing them such as peptone, casamino acid, yeast extract, and soybean protein decomposition products and the like are used, and when an auxotrophic variant which requires an amino acid or the like for its growth is used, it is necessary to complement the nutrient required.

[0054] As the inorganic salt, phosphates, magnesium salts, calcium salts, iron salts, manganese salts and the like are used.

[0055] As for the culture conditions, cultivation may be performed under aerobic conditions at a temperature of 20 to 42°C and a pH of 4 to 8. The cultivation can be continued for 10 hours to 4 days to accumulate a considerable amount of L-glutamic acid in the liquid culture medium.

[0056] After the completion of the cultivation, L-glutamic acid accumulated in the culture medium may be collected by a known method. For example, it can be isolated by a method comprising concentrating the medium after removing the cells to crystallize the product, ion exchange chromatography or the like.

## 50 Examples

[0057] The present invention will be explained more specifically with reference to the following examples.

(1) Construction of plasmid having *gltA* gene, *ppc* gene and *gdhA* gene

[0058] Procedure for construction of a plasmid having a *gltA* gene, a *ppc* gene and a *gdhA* gene will be explained by referring to Figure 1 to Figure 5.

[0059] A plasmid pBRGDH having a *gdhA* gene derived from *Escherichia coli* (Japanese Patent Application Laid-

EP 0 952 221 A2

Open (KOKAI) No. 7-203980(1995)) was digested with HindIII and *SphI*, and the both ends were blunt-ended by a treatment with T4 DNA polymerase. Then, a DNA fragment containing the *gdhA* gene was purified and collected. On the other hand, a plasmid pMWCP having a *gltA* gene and a *ppc* gene derived from *Escherichia coli* (WO97/08294) was digested with *XbaI*, and the both ends were blunt-ended by a treatment with T4 DNA polymerase. This was mixed with the DNA fragment having the *gdhA* gene purified above, and ligated with T4 ligase, giving a plasmid pMWCPG, which corresponds to the pMWCP further carrying the *gdhA* gene (Figure 1).

[0060] A DNA fragment having the *gdhA* gene obtained by digesting the pBRGDH with HindIII and *Sall* was purified and collected, and introduced into the *HindIII-Sall* site of a plasmid pSTV29 (purchased from Takara Shuzo) to obtain a plasmid pSTVG (Figure 2).

[0061] At the same time, a product obtained by digesting a plasmid pVIC40 having a replication origin of a wide-host-range plasmid RSF1010 (Japanese Patent Application Laid-Open (KOKAI) No. 8-047397(1996)) with *NotI*, followed by T4 DNA polymerase treatment and *PstI* digestion, and a product obtained by digesting pBR322 with EcoT141, followed by T4 DNA polymerase treatment and *PstI* digestion, were mixed and ligated with T4 ligase to obtain a plasmid RSF-Tet having the replication origin of RSF1010 and a tetracycline resistance gene (Figure 3).

[0062] Then, the pMWCPG was digested with EcoRI and *PstI*, and a DNA fragment having the *gltA* gene, the *ppc* gene and the *gdhA* gene was purified and collected. Similarly, the RSF-Tet was digested with EcoRI and *PstI*, and a DNA fragment having the replication origin of RSF1010 was purified and collected. Those DNA fragments were mixed and ligated with T4 ligase to obtain a plasmid RSFCPG composed of RSF-Tet carrying the *gltA* gene, the *ppc* gene and the *gdhA* gene (Figure 4). Expression of the *gltA* gene, the *ppc* gene and the *gdhA* gene by the resulting plasmid RSFCPG, and expression of the *gdhA* gene by the pSTVG were confirmed based on complementation of auxotrophy of *Escherichia coli* strains lacking the *gltA* gene, the *ppc* gene or the *gdhA* gene, and measurement of each enzyme activity.

[0063] A plasmid having a *gltA* gene derived from *Brevibacterium lactofermentum* was constructed as follows. PCR was performed by using primers having the nucleotide sequences represented in SEQ ID NOS: 6 and 7 selected based on the nucleotide sequence of the *gltA* gene of *Corynebacterium glutamicum* (Microbiology, 140, 1817-1828, 1994), and a chromosome DNA of *Brevibacterium lactofermentum* ATCC 13869 as a template to obtain a *gltA* gene fragment of about 3 kb. This fragment was inserted into a plasmid pHSG399 (purchased from Takara Shuzo) digested with *SmaI* to obtain a plasmid pHSGCB (Figure 5). Then, the pHSGCB was digested with HindIII, and an excised *gltA* gene fragment of about 3 kb was inserted into a plasmid pMW218 (purchased from Nippon Gene) digested with HindIII to obtain a plasmid pMWCB (Figure 5). Expression of the *gltA* gene by the resulting plasmid pMWCB was confirmed by determination of enzyme activity in the *Enterobacter agglomerans* AJ13355.

(2) Introduction of RSFCPG, pMWCB and pSTVG into *Enterobacter agglomerans* or *Serratia liquefacience*, and evaluation of L-glutamic acid productivity

[0064] The *Enterobacter agglomerans* ATCC 12287, the *Enterobacter agglomerans* AJ13355 and the *Serratia liquefacience* ATCC 14460 were transformed with the RSFCPG, pMWCB and pSTVG by electroporation (Miller J.H., "A Short Course in Bacterial Genetics; Handbook" Cold Spring Harbor Laboratory Press, USA, 1992) to obtain transformants exhibiting tetracycline resistance.

[0065] Each of the resulting transformants and the parent strains was inoculated into 50 ml-volume large size test tube containing 5 ml of a culture medium comprising 40 g/L glucose, 20 g/L ammonium sulfate, 0.5 g/L magnesium sulfate heptahydrate, 2 g/L potassium dihydrogenphosphate, 0.5 g/L sodium chloride, 0.25 g/L calcium chloride heptahydrate, 0.02 g/L ferrous sulfate heptahydrate, 0.02 g/L manganese sulfate tetrahydrate, 0.72 mg/L zinc sulfate dihydrate, 0.64 mg/L copper sulfate pentahydrate, 0.72 mg/L cobalt chloride hexahydrate, 0.4 mg/L boric acid, 1.2 mg/L sodium molybdate dihydrate, 2 g/L yeast extract, and 30 g/L calcium carbonate, and cultured at 37°C with shaking until the glucose contained in the culture medium was consumed. However, as for the AJ13355/pMWCB strain and the AJ13355/pSTVG strain, the cultivation was stopped when about 10 g/L of glucose was consumed, i.e., cultivated for 15 hours like the parent strain AJ13355, because their glucose consumption rates were low. To the culture medium of the transformants, 25 mg/L of tetracycline was added. After the cultivation was completed, L-glutamic acid accumulated in the culture medium was measured. The results are shown in Table 1.

Table 1:

Accumulated amount of L-glutamic acid	
Bacterial strain	Accumulated amount of L-glutamic acid
ATCC12287	0.0 g/L
ATCC12287/RSFCPG	6.1

Table 1: (continued)

Accumulated amount of L-glutamic acid	
Bacterial strain	Accumulated amount of L-glutamic acid
AJ13355	0.0
AJ13355/RSFCPG	3.3
AJ13355/pMWCB	0.8
AJ13355/pSTVG	0.8
ATCC14460	0.0
ATCC14460/RSFCPG	2.8
Culture medium alone	0.2

5

10

[0066] While the *Enterobacter agglomerans* ATCC12287, the *Enterobacter agglomerans* AJ13355 and the *Serratia liquefaciens* ATCC14460 did not accumulate L-glutamic acid, the strains whose CS, PEPC and GDH activities were amplified by introducing RSFCPG accumulated 6.1 g/L, 3.3 g/L, and 2.8 g/L of L-glutamic acid, respectively. The AJ13355 strain of which CS activity alone was amplified accumulated 0.8 g/L of L-glutamic acid, and the strain of which GDH activity alone was amplified also accumulated 0.8 g/L of L-glutamic acid.

20 (3) Cloning of  $\alpha$ KGDH gene (referred to as "sucAB" hereinafter) of *Enterobacter agglomerans* AJ13355

[0067] The *sucAB* gene of the *Enterobacter agglomerans* AJ13355 was cloned by selecting a DNA fragment complementing acetate non-assimilation of an *Escherichia coli* strain lacking the  $\alpha$ KGDH-E1 subunit gene (referred to as "sucA" hereinafter) from the chromosome DNA of the *Enterobacter agglomerans* AJ13355.

25 [0068] The chromosome DNA of the *Enterobacter agglomerans* AJ13355 strain was isolated by the same method as conventionally used for extracting chromosome DNA from *Escherichia coli* (Seibutsu Kogaku Jikken-sho (Textbook of Bioengineering Experiments), Ed. by the Society of Fermentation and Bioengineering, Japan, p.97-98, Baifukan, 1992). The pTWV228 used as the vector (ampicillin resistant) was a marketed product from Takara Shuzo.

30 [0069] Products obtained by digesting the chromosome DNA of the AJ13355 strain with *Eco*T221 and products obtained by digesting the pTWV228 with *Pst*I were ligated by T4 ligase, and the *Escherichia coli* JRG465 lacking *sucA* (Herbert J. et al., Mol. Gen. Genetics, 1969, 105, p.182) was transformed with them. Strains grown on the acetic acid minimal medium were selected from the transformants obtained as described above, and a plasmid extracted from them was designated as pTWVEK101. The *Escherichia coli* JRG465 carrying the pTWVEK101 recovered the characteristics of acetate non-assimilability as well as auxotrophy for succinic acid or L-lysine and L-methionine. This suggests that the pTWVEK101 contains the *sucA* gene of *Enterobacter agglomerans*.

35 [0070] A restriction map of *Enterobacter agglomerans*-derived DNA fragment of pTWVEK101 is shown in Figure 6. The result of nucleotide sequencing of the hatched portion in Figure 6 is shown in SEQ ID NO: 1. In this sequence, two full length ORFs and two nucleotides sequences considered as partial sequences of ORFs were found. Amino acid sequences that can be encoded by these ORFs and the partial sequences thereof are shown in SEQ ID NOS: 2 to 5 in order from the 5' ends. As a result of homology analysis of these sequences, it was found that the portion of which nucleotide sequence had been determined contained a 3' partial sequence of succinate dehydrogenase iron-sulfur protein gene (*sdhB*), full length *sucA* and  $\alpha$ KGDH-E2 subunit gene (*sucB* gene), and 5' partial sequence of succinyl-CoA synthetase  $\beta$  subunit gene (*sucC* gene). Comparison of the amino acid sequences deduced from these nucleotide sequences with those of *Escherichia coli* (Eur. J. Biochem., 141, 351-359 (1984), Eur. J. Biochem., 141, 361-374 (1984), and Biochemistry, 24, 6245-6252 (1985)) is shown in Figures 7 to 9. As shown by these results, the amino acid sequences exhibited markedly high homology. It was also found that a cluster of *sdhB-sucA-sucB-sucC* is formed on the *Enterobacter agglomerans* chromosome like *Escherichia coli* (Eur. J. Biochem., 141, 351-359 (1984), Eur. J. Biochem., 141, 361-374 (1984), and Biochemistry, 24, 6245-6252 (1985)).

40 50 (4) Acquisition of strain deficient in  $\alpha$ KGDH derived from *Enterobacter agglomerans* AJ13355

[0071] Using the *sucAB* gene of *Enterobacter agglomerans* obtained as described above, a strain lacking  $\alpha$ KGDH of *Enterobacter agglomerans* was obtained by homologous recombination.

55 [0072] First, pTWVEK101 was digested with *Bgl*II to remove the C-terminus region corresponding to about half of the *sucA* gene and the full length of the *sucB* gene. To this site, a chloramphenicol resistance gene fragment cut out from the pHSG399 (Takara Shuzo) with *Acc*I was then inserted. The region of *sdhB-ΔsucAB::Cm<sup>r</sup>-sucC* obtained above was cut out with *Afl*II and *Sac*I. The resulting DNA fragment was used to transform the *Enterobacter agglomerans*

EP 0 952 221 A2

AJ13355 strain by electroporation to obtain a chloramphenicol resistant strain, and thus a *Enterobacter agglomerans* AJ13356 strain lacking the *sucAB* gene where the *sucAB* gene on the chromosome was replaced by *sucAB::Cm'* was obtained.

[0073] To confirm that the AJ13356 strain obtained as described above was deficient in the  $\alpha$ KGDH activity, its enzymatic activity was determined by the method of Reed (L.J. Reed and B.B. Mukherjee, Methods in Enzymology 1969, 13, p.55-61). As a result, the  $\alpha$ KGDH activity could not be detected in the AJ13356 strain as shown in Table 2, and thus it was confirmed that the strain lacked the *sucAB* as desired.

Table 2:

$\alpha$ KGDH activity	
Bacterial strain	$\alpha$ KGDH activity ( $\Delta$ ABS/min/mg protein)
AJ13355	0.481
AJ13356	<0.0001

(5) Evaluation of L-glutamic acid productivity of *Enterobacter agglomerans* strain deficient in  $\alpha$ KGDH

[0074] Each of the AJ13355 and AJ13356 strains was inoculated into a 500 ml-volume flask containing 20 ml of a culture medium comprising 40 g/L glucose, 20 g/L ammonium sulfate, 0.5 g/L magnesium sulfate heptahydrate, 2 g/L potassium dihydrogenphosphate, 0.5 g/L sodium chloride, 0.25 g/L calcium chloride heptahydrate, 0.02 g/L ferrous sulfate heptahydrate, 0.02 g/L manganese sulfate tetrahydrate, 0.72 mg/L zinc sulfate dihydrate, 0.64 mg/L copper sulfate pentahydrate, 0.72 mg/L cobalt chloride hexahydrate, 0.4 mg/L boric acid, 1.2 mg/L sodium molybdate dihydrate, 2 g/L yeast extract, 30 g/L calcium carbonate, 200 mg/L L-lysine monohydrochloride, 200 mg/L L-methionine and 200 mg/L DL- $\alpha$ , $\epsilon$ -diaminopimelic acid (DAP), and cultured at 37°C with shaking until the glucose contained in the culture medium was consumed. After the cultivation was completed, L-glutamic acid and  $\alpha$ -ketoglutaric acid (abbreviated as "aKG" hereinafter) accumulated in the culture medium were measured. The results are shown in Table 3.

Table 3:

Accumulated amounts of L-glutamic acid and aKG		
Bacterial strain	Accumulated amount of L-glutamic acid	Accumulated amount of aKG
AJ13355	0.0 g/L	0.0 g/L
AJ13356	1.5	3.2

[0075] The AJ13356 strain deficient in the  $\alpha$ KGDH activity accumulated 1.5 g/L of L-glutamic acid, and simultaneously accumulated 3.2 g/L of aKG.

(6) Introduction of RSFCPG into *Enterobacter agglomerans* strain lacking  $\alpha$ KGDH and evaluation of L-glutamic acid productivity

[0076] The AJ13356 strain was transformed with the RSFCPG, and the resulting strain introduced with the RSFCPG, AJ13356/RSFCPG, was inoculated into a 500 ml-volume flask containing 20 ml of a culture medium comprising 40 g/L glucose, 20 g/L ammonium sulfate, 0.5 g/L magnesium sulfate heptahydrate, 2 g/L potassium dihydrogenphosphate, 0.5 g/L sodium chloride, 0.25 g/L calcium chloride heptahydrate, 0.02 g/L ferrous sulfate heptahydrate, 0.02 g/L manganese sulfate tetrahydrate, 0.72 mg/L zinc sulfate dihydrate, 0.64 mg/L copper sulfate pentahydrate, 0.72 mg/L cobalt chloride hexahydrate, 0.4 mg/L boric acid, 1.2 mg/L sodium molybdate dihydrate, 2 g/L yeast extract, 25 mg/L tetracycline, 30 g/L calcium carbonate, 200 mg/L L-lysine monohydrochloride, 200 mg/L L-methionine and 200 mg/L DL- $\alpha$ , $\epsilon$ -DAP, and cultured at 37°C with shaking until the glucose contained in the culture medium was consumed. After the cultivation was completed, L-glutamic acid and aKG accumulated in the culture medium were measured. The results are shown in Table 4.

Table 4:

Accumulated amounts of L-glutamic acid and aKG		
Bacterial strain	Accumulated amount of L-glutamic acid	Accumulated amount of aKG
AJ13356	1.4 g/L	2.9 g/L

EP 0 952 221 A2

Table 4: (continued)

Accumulated amounts of L-glutamic acid and $\alpha$ KG		
Bacterial strain	Accumulated amount of L-glutamic acid	Accumulated amount of $\alpha$ KG
AJ13356/RSFCPG	5.1	0.0

[0077] In the strain of which CS, PEPC and GDH activities were amplified by the introduction of RSFCPG, the accumulated amount of  $\alpha$ KG was reduced, and the accumulated amount of L-glutamic acid was further improved.

10

15

20

25

30

35

40

45

50

55

EP 0 952 221 A2

Annex to the description

[0078]

5

10

15

20

25

30

35

40

45

50

55

## SEQUENCE LISTING

5 <110> Ajinomoto Co., Inc.

10 <120> L-Glutamic acid-producing bacterium and method for producing L-glutamic acid

15 <130> EPA-53126

20 <150> JP 10-69068

25 <151> 1998-03-18

30 <150> JP 10-297129

35 <151> 1998-10-19

40 <160> 7

45 <170> PatentIn Ver. 2.0

50 <210> 1

55 <211> 4556

60 <212> DNA

65 <213> Enterobacter agglomerans

70 <220>

75 <221> CDS

80 <222> (2)..(121)

85 <220>

90 <221> CDS

95 <222> (322)..(3129)

100 <220>

105 <221> CDS

110 <222> (3145)..(4368)

115 <220>

120 <221> CDS

125 <222> (4437)..(4556)

130 <400> 1

135 t gca ttc agc gtt ttc cgc tgt cac agc atc atg aac tgt gta agt gtt 49

140 Ala Phe Ser Val Phe Arg Cys His Ser Ile Met Asn Cys Val Ser Val

145 1 5 10 15

150 tgt cct aaa ggg cta aac ccg acg cgc gct atc ggc cac att aag tcg 97

155 Cys Pro Lys Gly Leu Asn Pro Thr Arg Ala Ile Gly His Ile Lys Ser

160 20 25 30

165 atg ctg ctg caa cgc agc gcg tagttataacc accggaaacc tcaggttccc 148

170 Met Leu Leu Gln Arg Ser Ala

175 35

180 ggtatttac ggaaggctct gtaaacgcgg tcccaaccac gtttacaaag gttcccttac 208

185 gggccggcgc cgccgtgcgc acagtgtcg tatcgctgaa ctcaactacgg caaaccgcga 268

190 aagcggcaac aaatgaaacc tcaaaaaagc ataacattgc ttaaggatc aca atg 324

195 Met

200 1

205 cag aac agc gcg atg aag ccc tgg ctg gac tcc tcc tgg ctg gcc ggc 372

210 Gln Asn Ser Ala Met Lys Pro Trp Leu Asp Ser Ser Trp Leu Ala Gly

215 5 10 15

## EP 0 952 221 A2

5	gct aat cag tct tac ata gag caa ctc tat gag gat ttc ctg acc gat Ala Asn Gln Ser Tyr Ile Glu Gln Leu Tyr Glu Asp Phe Leu Thr Asp 20 25 30	420
10	cct gac tct gtg gat gca gtg tgg cgc tcg atg ttc caa cag tta cca Pro Asp Ser Val Asp Ala Val Trp Arg Ser Met Phe Gln Gln Leu Pro 35 40 45	468
15	ggc acg gga gtg aaa cct gag cag ttc cac tcc gca act cgc gaa tat Gly Thr Gly Val Lys Pro Glu Gln Phe His Ser Ala Thr Arg Glu Tyr 50 55 60 65	516
20	ttc cgt cgc ctg gcg aaa gac gca tct cgt tac acc tcc tca gtt acc Phe Arg Arg Leu Ala Lys Asp Ala Ser Arg Tyr Thr Ser Ser Val Thr 70 75 80	564
25	gat ccg gca acc aac tcc aaa caa gtg aaa gtg ctg cag ctg att aac Asp Pro Ala Thr Asn Ser Lys Gln Val Lys Val Leu Gln Leu Ile Asn 85 90 95	612
30	gct ttt cgt ttc cgc gga cat cag gaa gca aat ctc gat ccg ctt ggc Ala Phe Arg Phe Arg Gly His Gln Glu Ala Asn Leu Asp Pro Leu Gly 100 105 110	660
35	ctg tgg aaa cag gac cgc gtt gcc gat ctc gat cct gcc ttt cac gat Leu Trp Lys Gln Asp Arg Val Ala Asp Leu Asp Pro Ala Phe His Asp 115 120 125	708
40	ctg acc gac gcc gat ttt cag gaa agc ttt aac gta ggt tct ttt gcc Leu Thr Asp Ala Asp Phe Gln Glu Ser Phe Asn Val Gly Ser Phe Ala 130 135 140 145	756
45	att ggc aaa gaa acc atg aag ctg gcc gat ctg ttc gac gcg ctg aag Ile Gly Lys Glu Thr Met Lys Leu Ala Asp Leu Phe Asp Ala Leu Lys 150 155 160	804
50	cag acc tac tgt ggc tcg att ggt gca gag tat atg cac atc aat aac Gln Thr Tyr Cys Gly Ser Ile Gly Ala Glu Tyr Met His Ile Asn Asn 165 170 175	852
55	acc gaa gag aaa cgc tgg atc cag cag cgt atc gaa tcc ggt gcg agc Thr Glu Glu Lys Arg Trp Ile Gln Gln Arg Ile Glu Ser Gly Ala Ser 180 185 190	900
60	cag acg tca ttc agt ggc gaa gag aaa aaa ggt ttc ctg aaa gag ctg Gln Thr Ser Phe Ser Gly Glu Glu Lys Lys Gly Phe Leu Lys Glu Leu 195 200 205	948
65	acc gcg gca gaa ggg ctg gaa aaa tat ctg ggc gcg aaa ttc ccg ggt Thr Ala Ala Glu Gly Leu Glu Lys Tyr Leu Gly Ala Lys Phe Pro Gly 210 215 220 225	996
70	gca aaa cgt ttc tcg ctg gaa ggc ggt gat gcg ctg gtg ccg atg ctg Ala Lys Arg Phe Ser Leu Glu Gly Gly Asp Ala Leu Val Pro Met Leu 230 235 240	1044
75	cgc gag atg att cgt cat gcg ggc aaa agc ggc aca cgt gaa gtg gta Arg Glu Met Ile Arg His Ala Gly Lys Ser Gly Thr Arg Glu Val Val 245 250 255	1092
80	ctg ggg atg gcg cac cgt ggc cgt ctt aac gta ctg att aac gta ctg Leu Gly Met Ala His Arg Gly Arg Leu Asn Val Leu Ile Asn Val Leu	1140

## EP 0 952 221 A2

	260	265	270		
5	ggt aaa aag cca cag gat ctg ttc gac gaa ttc tcc ggt aaa cac aaa Gly Lys Lys Pro Gln Asp Leu Phe Asp Glu Phe Ser Gly Lys His Lys	275	280	285	1188
10	gag cat ctg ggc acc ggt gat gtg aag tat cac atg ggc ttc tct tcg Glu His Leu Gly Thr Gly Asp Val Lys Tyr His Met Gly Phe Ser Ser	290	295	300	1236
15	gat att gaa acc gaa ggt ggt ctg gtg cat ctg gcg ctg gcg ttt aac Asp Ile Glu Thr Glu Gly Leu Val His Leu Ala Leu Ala Phe Asn	310	315	320	1284
20	ccg tct cac ctg gaa att gtc agc ccg gtg gtc atg gga tcg gta cgt Pro Ser His Leu Glu Ile Val Ser Pro Val Val Met Gly Ser Val Arg	325	330	335	1332
25	gca cgt ctc gat cgt ctg gcc gaa ccg gtc agc aat aaa gtg ttg cct Ala Arg Leu Asp Arg Leu Ala Glu Pro Val Ser Asn Lys Val Leu Pro	340	345	350	1380
30	atc acc att cac ggt gat gcg gcg gtg att ggt cag ggc gtg gtt cag Ile Thr Ile His Gly Asp Ala Ala Val Ile Gly Gln Gly Val Val Gln	355	360	365	1428
35	gaa acc ctg aac atg tct cag gcg cgc ggc tac gaa gtg ggc ggc acg Glu Thr Leu Asn Met Ser Gln Ala Arg Gly Tyr Glu Val Gly Gly Thr	370	375	380	1476
40	gta cgt atc gtc att aac aac cag gtt ggt ttt acc acc tcc aac ccg Val Arg Ile Val Ile Asn Asn Gln Val Gly Phe Thr Thr Ser Asn Pro	390	395	400	1524
45	aaa gat gcg cgt tca acc ccg tac tgt act gac atc ggc aag atg gtg Lys Asp Ala Arg Ser Thr Pro Tyr Cys Thr Asp Ile Gly Lys Met Val	405	410	415	1572
50	ctg gca ccg att ttc cac gtc aat gct gac gat ccg gaa gcg gtg gcc Leu Ala Pro Ile Phe His Val Asn Ala Asp Asp Pro Glu Ala Val Ala	420	425	430	1620
55	ttt gtt acc cgc ctg gcg ctg gac tat cgc aac acc ttc aaa cgc gat Phe Val Thr Arg Leu Ala Leu Asp Tyr Arg Asn Thr Phe Lys Arg Asp	435	440	445	1668
	gtg ttt atc gat ctg gtg tgc tat cgc cgt cat ggt cac aac gag gcg Val Phe Ile Asp Leu Val Cys Tyr Arg Arg His Gly His Asn Glu Ala	450	455	460	1716
	gat gag cca agt gct acc cag ccg ttg atg tac cag aaa atc aaa aag Asp Glu Pro Ser Ala Thr Gln Pro Leu Met Tyr Gln Lys Ile Lys Lys	470	475	480	1764
	cat ccg acg ccg cgt aaa att tac gcc gat cgt ctg gaa ggc gaa ggt His Pro Thr Pro Arg Lys Ile Tyr Ala Asp Arg Leu Glu Gly Glu Gly	485	490	495	1812
	gtc gcg tcg cag gaa gat gcc acc gag atg gtg aac ctg tac cgc gat Val Ala Ser Gln Glu Asp Ala Thr Glu Met Val Asn Leu Tyr Arg Asp	500	505	510	1860
	gcg ctc gat gcg ggc gaa tgc gtg gtg ccg gaa tgg cgt ccg atg agc				1908

## EP 0 952 221 A2

	Ala Leu Asp Ala Gly Glu Cys Val Val Pro Glu Trp Arg Pro Met Ser		
5	515 520 525		
	ctg cac tcc ttc acg tgg tcg cct tat ctg aac cac gaa tgg gat gag		1956
	Leu His Ser Phe Thr Trp Ser Pro Tyr Leu Asn His Glu Trp Asp Glu		
	530 535 540 545		
10	cct tat ccg gca cag gtt gac atg aaa cgc ctg aag gaa ctg gca ttg		2004
	Pro Tyr Pro Ala Gln Val Asp Met Lys Arg Leu Lys Glu Leu Ala Leu		
	550 555 560		
	cgt atc agc cag gtc cct gag cag att gaa gtt cag tcg cgc gtt gcc		2052
	Arg Ile Ser Gln Val Pro Glu Gln Ile Glu Val Gln Ser Arg Val Ala		
	565 570 575		
15	aag atc tat aac gat cgc aag ctg atg gcc gaa ggc gag aaa gct ttc		2100
	Lys Ile Tyr Asn Asp Arg Lys Leu Met Ala Glu Gly Glu Lys Ala Phe		
	580 585 590		
20	gac tgg ggc ggt gcc gag aat ctg gct tac gcc acg ctg gtt gat gaa		2148
	Asp Trp Gly Gly Ala Glu Asn Leu Ala Tyr Ala Thr Leu Val Asp Glu		
	595 600 605		
	ggt att ccg gtt cgc ctc tcg ggt gaa gac tcc ggt cgt gga acc ttc		2196
	Gly Ile Pro Val Arg Leu Ser Gly Glu Asp Ser Gly Arg Gly Thr Phe		
	610 615 620 625		
25	ttc cat cgc cac gct gtc gtg cac aac cag gct aac ggt tca acc tat		2244
	Phe His Arg His Ala Val Val His Asn Gln Ala Asn Gly Ser Thr Tyr		
	630 635 640		
30	acg ccg ctg cac cat att cat aac agc cag ggc gag ttc aaa gtc tgg		2292
	Thr Pro Leu His His Ile His Asn Ser Gln Gly Glu Phe Lys Val Trp		
	645 650 655		
	gat tcg gtg ctg tct gaa gaa gct gtg ctg gct ttt gaa tac ggt tac		2340
	Asp Ser Val Leu Ser Glu Glu Ala Val Leu Ala Phe Glu Tyr Gly Tyr		
35	660 665 670		
	gcc acg gct gag ccg cgc gtg ctg acc atc tgg gaa gct cag ttt ggt		2388
	Ala Thr Ala Glu Pro Arg Val Leu Thr Ile Trp Glu Ala Gln Phe Gly		
	675 680 685		
40	gac ttt gcc aac ggt gct cag gtg gtg att gac cag ttc atc agc tct		2436
	Asp Phe Ala Asn Gly Ala Gln Val Val Ile Asp Gln Phe Ile Ser Ser		
	690 695 700 705		
	ggc gaa cag aag tgg ggc cgt atg tgt ggc ctg gtg atg ttg ctg ccg		2484
	Gly Glu Gln Lys Trp Gly Arg Met Cys Gly Leu Val Met Leu Leu Pro		
45	710 715 720		
	cat ggc tac gaa ggt cag gga ccg gaa cac tcc tct gcc cgt ctg gaa		2532
	His Gly Tyr Glu Gly Gln Gly Pro Glu His Ser Ser Ala Arg Leu Glu		
	725 730 735		
50	cgc tat ctg caa ctt tgc gcc gag cag aac atg cag gtt tgc gtc ccg		2580
	Arg Tyr Leu Gln Leu Cys Ala Glu Gln Asn Met Gln Val Cys Val Pro		
	740 745 750		
55	tcg acg ccg gct cag gtt tat cac atg ctg cgc cgt cag gct ctg ccg		2628
	Ser Thr Pro Ala Gln Val Tyr His Met Leu Arg Arg Gln Ala Leu Arg		
	755 760 765		

## EP 0 952 221 A2

	ggg atg cgc cgt ccg ctg gtg atg tcg ccg aag tcg ctg tta cgc	2676
	Gly Met Arg Arg Pro Leu Val Val Met Ser Pro Lys Ser Leu Leu Arg	
5	770 775 780 785	
	cat cca ctg gcg atc tcg tcg gat gaa ctg gca aac ggc agt ttc	2724
	His Pro Leu Ala Ile Ser Ser Leu Asp Glu Leu Ala Asn Gly Ser Phe	
	790 795 800	
10	cag ccg gcc att ggt gag atc gac gat ctg gat ccg cag ggc gtg aaa	2772
	Gln Pro Ala Ile Gly Glu Ile Asp Asp Leu Asp Pro Gln Gly Val Lys	
	805 810 815	
	cgc gtc gtg ctg tgc tcc ggt aag gtt tac tac gat ctg ctg gaa cag	2820
	Arg Val Val Leu Cys Ser Gly Lys Val Tyr Tyr Asp Leu Leu Glu Gln	
15	820 825 830	
	cgt cgt aaa gac gag aaa acc gat gtt gcc atc gtg cgc atc gaa cag	2868
	Arg Arg Lys Asp Glu Lys Thr Asp Val Ala Ile Val Arg Ile Glu Gln	
	835 840 845	
20	ctt tac ccg ttc ccg cat cag gcg gta cag gaa gca ttg aaa gcc tat	2916
	Leu Tyr Pro Phe Pro His Gln Ala Val Gln Glu Ala Leu Lys Ala Tyr	
	850 855 860 865	
	tct cac gta cag gac ttt gtc tgg tgc cag gaa gag cct ctg aac cag	2964
	Ser His Val Gln Asp Phe Val Trp Cys Gln Glu Glu Pro Leu Asn Gln	
25	870 875 880	
	ggc gcc tgg tac tgt agc cag cat cat ttc cgt gat gtc gtg ccg ttt	3012
	Gly Ala Trp Tyr Cys Ser Gln His His Phe Arg Asp Val Val Pro Phe	
	885 890 895	
30	ggt gcc acc ctg cgt tat gca ggt cgc ccg gca tcg gct tct ccg gcc	3060
	Gly Ala Thr Leu Arg Tyr Ala Gly Arg Pro Ala Ser Ala Ser Pro Ala	
	900 905 910	
	gtg ggt tat atg tcc gta cac caa caa cag cag caa gac ctg gtt aat	3108
	Val Gly Tyr Met Ser Val His Gln Gln Gln Gln Asp Leu Val Asn	
35	915 920 925	
	gac gca ctg aac gtc aat taattaaaag gaaagata atg agt agc gta gat	3159
	Asp Ala Leu Asn Val Asn Met Ser Ser Val Asp	
	930 935 1 5	
40	att ctc gtt ccc gac ctg cct gaa tcg gtt gca gat gcc aca gta gca	3207
	Ile Leu Val Pro Asp Leu Pro Glu Ser Val Ala Asp Ala Thr Val Ala	
	10 15 20	
45	acc tgg cac aag aaa cca ggc gat gca gtc agc cgc gat gaa gtc atc	3255
	Thr Trp His Lys Lys Pro Gly Asp Ala Val Ser Arg Asp Glu Val Ile	
	25 30 35	
	gtc gaa att gaa act gac aaa gtc gtg ctg gaa gtg ccg gca tct gcc	3303
	Val Glu Ile Glu Thr Asp Lys Val Val Leu Glu Val Pro Ala Ser Ala	
50	40 45 50	
	gat ggc gtg ctg gaa gcc gtg ctg gaa gac gaa ggg gca acc gtt acg	3351
	Asp Gly Val Leu Glu Ala Val Leu Glu Asp Glu Gly Ala Thr Val Thr	
	55 60 65	
55	tcc cgc cag atc ctg ggt cgc ctg aaa gaa ggc aac agt gcg ggt aaa	3399
	Ser Arg Gln Ile Leu Gly Arg Leu Lys Glu Gly Asn Ser Ala Gly Lys	

## EP 0 952 221 A2

	70	75	80	85														
	gaa	agc	agt	gcc	aaa	gcg	gaa	agc	aat	gac	acc	acg	cca	gcc	cag	cgt		3447
5	Glu	Ser	Ser	Ala	Lys	Ala	Glu	Ser	Asn	Asp	Thr	Thr	Pro	Ala	Gln	Arg		
	90						95						100					
	cag	aca	gca	tcg	ctt	gaa	gaa	gag	agc	agc	gat	gct	ctc	agc	ccg	gct		3495
	Gln	Thr	Ala	Ser	Leu	Glu	Glu	Glu	Ser	Ser	Asp	Ala	Leu	Ser	Pro	Ala		
10																		3543
	105						110											
	atc	cgt	cgc	ctg	att	gct	gag	cat	aat	ctt	gac	gct	gct	cag	atc	aaa		
	Ile	Arg	Arg	Leu	Ile	Ala	Glu	His	Asn	Leu	Asp	Ala	Ala	Gln	Ile	Lys		
15																		3591
	120						125											
	ggc	acc	ggc	gta	ggc	gga	cgt	tta	acg	cgt	gaa	gac	gtt	gaa	aaa	cat		
	Gly	Thr	Gly	Val	Gly	Gly	Arg	Leu	Thr	Arg	Glu	Asp	Val	Glu	Lys	His		
20																		3639
	135						140											
	ctg	gct	gac	aaa	ccg	cag	gct	gag	aaa	gcc	gcc	gct	cca	gct	gct	ggt		
	Leu	Ala	Asn	Lys	Pro	Gln	Ala	Glu	Lys	Ala	Ala	Ala	Pro	Ala	Ala	Gly		
25																		3687
	150						155											
	gca	gca	acg	gct	cag	cag	cct	gtt	gcc	aac	cgc	agc	gaa	aaa	cgt	gtt		
	Ala	Ala	Thr	Ala	Gln	Gln	Pro	Val	Ala	Asn	Arg	Ser	Glu	Lys	Arg	Val		
30																		3735
	170						175											
	ccg	atg	acg	cgt	tta	cgt	aag	cgc	gtc	gct	gag	cgt	ctg	gtt	gaa	gcc		
	Pro	Met	Thr	Arg	Leu	Arg	Lys	Arg	Val	Ala	Glu	Arg	Leu	Leu	Glu	Ala		
35							185			190								3783
	180						195											
	aag	aac	agc	acc	gcc	atg	ttg	acg	acc	ttc	aac	gaa	atc	aac	atg	aag		
	Lys	Asn	Ser	Thr	Ala	Met	Leu	Thr	Thr	Phe	Asn	Glu	Ile	Asn	Met	Lys		
40																		3831
	200						205											
	ccg	att	atg	gat	ctg	cgt	aag	cag	tac	ggc	gat	gct	ttc	gag	aag	cgt		
	Pro	Ile	Met	Asp	Leu	Arg	Lys	Gln	Tyr	Gly	Asp	Ala	Phe	Glu	Lys	Arg		
45							215			220								3879
	210						225											
	cac	ggt	gtg	cgt	ctg	ggc	ttt	atg	tct	tac	atc	aag	gcc	gtg	gtc			
	His	Gly	Val	Arg	Leu	Gly	Phe	Met	Ser	Phe	Tyr	Ile	Lys	Ala	Val	Val		
50							230			235								3927
	220						240			245								
	gaa	gct	ctg	aag	cgt	tat	cca	gaa	gtc	aac	gcc	tct	atc	gat	ggc	gaa		
	Glu	Ala	Leu	Lys	Arg	Tyr	Pro	Glu	Val	Asn	Ala	Ser	Ile	Asp	Gly	Glu		
55							250			255								3975
	240						260			265								
	gac	gtg	gtg	tac	cac	aac	tat	ttc	gat	gtg	agt	att	gcc	gtc	tct	acg		
	Asp	Val	Val	Tyr	His	Asn	Tyr	Phe	Asp	Val	Ser	Ile	Ala	Val	Ser	Thr		
60							265			270								4023
	255						275											
	cca	cgc	gga	ctg	gtg	acg	cct	gtc	ctg	cgt	gac	gtt	gat	gct	ctg	acg		
	Pro	Arg	Gly	Leu	Val	Thr	Pro	Val	Leu	Arg	Asp	Val	Asp	Ala	Leu	Ser		
65							280			285								4071
	270						290											
	atg	gct	gac	atc	gag	aag	aaa	att	aaa	gaa	ctg	gca	gtg	aaa	ggc	cgt		
	Met	Ala	Asp	Ile	Glu	Lys	Lys	Ile	Lys	Glu	Leu	Ala	Val	Lys	Gly	Arg		
70							295			300								4119
	285						305											
	gac	ggc	aag	ctg	acg	gtt	gac	gat	ctg	acg	ggc	ggt	aac	ttt	acc	atc		
	Asp	Gly	Lys	Leu	Thr	Val	Asp	Asp	Leu	Thr	Gly	Gly	Asn	Phe	Thr	Ile		
75							310			315								4167
	300						320			325								
	acc	aac	ggt	ggt	gtg	ttc	ggt	tcg	ctg	atg	tct	acg	cca	atc	atc	aac		

## EP 0 952 221 A2

Thr Asn Gly Gly Val Phe Gly Ser Leu Met Ser Thr Pro Ile Ile Asn  
 330 335 340  
 5 ccg cca cag agc gcg att ctg ggc atg cac gcc att aaa gat cgt cct 4215  
 Pro Pro Gln Ser Ala Ile Leu Gly Met His Ala Ile Lys Asp Arg Pro  
 345 350 355  
 atg gcg gtc aat ggt cag gtt gtg atc ctg cca atg atg tac ctg gct 4263  
 Met Ala Val Asn Gly Gln Val Val Ile Leu Pro Met Met Tyr Leu Ala  
 360 365 370  
 10 ctc tcc tac gat cac cgt tta atc gat ggt cgt gaa tct gtc ggc tat 4311  
 Leu Ser Tyr Asp His Arg Leu Ile Asp Gly Arg Glu Ser Val Gly Tyr  
 375 380 385  
 15 ctg gtc gcg gtg aaa gag atg ctg gaa gat ccg gcg cgt ctg ctg ctg 4359  
 Leu Val Ala Val Lys Glu Met Leu Glu Asp Pro Ala Arg Leu Leu  
 390 395 400 405  
 20 gat gtc tgattcatca ctggcacgc gttgcgtgcc caatctcaat actctttca 4415  
 Asp Val  
 gatctgaatg gatagaacat c atg aac tta cac gaa tac cag gct aaa cag 4466  
 Met Asn Leu His Glu Tyr Gln Ala Lys Gln  
 1 5 10  
 25 ctg ttt gca cgg tat ggc atg cca gca ccg acc ggc tac gcc tgt act 4514  
 Leu Phe Ala Arg Tyr Gly Met Pro Ala Pro Thr Gly Tyr Ala Cys Thr  
 15 20 25  
 30 aca cca cgt gaa gca gaa gaa gcg gca tcg aaa atc ggt gca 4556  
 Thr Pro Arg Glu Ala Glu Ala Ala Ser Lys Ile Gly Ala  
 30 35 40  
 35 <210> 2  
 <211> 39  
 <212> PRT  
 <213> Enterobacter agglomerans  
 <400> 2  
 Ala Phe Ser Val Phe Arg Cys His Ser Ile Met Asn Cys Val Ser Val  
 1 5 10 15  
 40 Cys Pro Lys Gly Leu Asn Pro Thr Arg Ala Ile Gly His Ile Lys Ser  
 20 25 30  
 Met Leu Leu Gln Arg Ser Ala  
 45 35  
 <210> 3  
 <211> 935  
 <212> PRT  
 <213> Enterobacter agglomerans  
 <400> 3  
 Met Gln Asn Ser Ala Met Lys Pro Trp Leu Asp Ser Ser Trp Leu Ala  
 1 5 10 15  
 50 Gly Ala Asn Gln Ser Tyr Ile Glu Gln Leu Tyr Glu Asp Phe Leu Thr

## EP 0 952 221 A2

	20	25	30
	Asp Pro Asp Ser Val Asp Ala Val Trp Arg Ser Met Phe Gln Gln Leu		
5	35	40	45
	Pro Gly Thr Gly Val Lys Pro Glu Gln Phe His Ser Ala Thr Arg Glu		
	50	55	60
	Tyr Phe Arg Arg Leu Ala Lys Asp Ala Ser Arg Tyr Thr Ser Ser Val		
	65	70	75
10	Thr Asp Pro Ala Thr Asn Ser Lys Gln Val Lys Val Leu Gln Leu Ile		
	85	90	95
	Asn Ala Phe Arg Phe Arg Gly His Gln Glu Ala Asn Leu Asp Pro Leu		
	100	105	110
15	Gly Leu Trp Lys Gln Asp Arg Val Ala Asp Leu Asp Pro Ala Phe His		
	115	120	125
	Asp Leu Thr Asp Ala Asp Phe Gln Glu Ser Phe Asn Val Gly Ser Phe		
	130	135	140
20	Ala Ile Gly Lys Glu Thr Met Lys Leu Ala Asp Leu Phe Asp Ala Leu		
	145	150	155
	Lys Gln Thr Tyr Cys Gly Ser Ile Gly Ala Glu Tyr Met His Ile Asn		
	165	170	175
25	Asn Thr Glu Glu Lys Arg Trp Ile Gln Gln Arg Ile Glu Ser Gly Ala		
	180	185	190
	Ser Gln Thr Ser Phe Ser Gly Glu Glu Lys Gly Phe Leu Lys Glu		
	195	200	205
	Leu Thr Ala Ala Glu Gly Leu Glu Lys Tyr Leu Gly Ala Lys Phe Pro		
30	210	215	220
	Gly Ala Lys Arg Phe Ser Leu Glu Gly Gly Asp Ala Leu Val Pro Met		
	225	230	235
	Leu Arg Glu Met Ile Arg His Ala Gly Lys Ser Gly Thr Arg Glu Val		
35	245	250	255
	Val Leu Gly Met Ala His Arg Gly Arg Leu Asn Val Leu Ile Asn Val		
	260	265	270
	Leu Gly Lys Lys Pro Gln Asp Leu Phe Asp Glu Phe Ser Gly Lys His		
	275	280	285
40	Lys Glu His Leu Gly Thr Gly Asp Val Lys Tyr His Met Gly Phe Ser		
	290	295	300
	Ser Asp Ile Glu Thr Glu Gly Leu Val His Leu Ala Leu Ala Phe		
	305	310	315
45	Asn Pro Ser His Leu Glu Ile Val Ser Pro Val Val Met Gly Ser Val		
	325	330	335
	Arg Ala Arg Leu Asp Arg Leu Ala Glu Pro Val Ser Asn Lys Val Leu		
	340	345	350
50	Pro Ile Thr Ile His Gly Asp Ala Ala Val Ile Gly Gln Gly Val Val		
	355	360	365
	Gln Glu Thr Leu Asn Met Ser Gln Ala Arg Gly Tyr Glu Val Gly Gly		
	370	375	380
55	Thr Val Arg Ile Val Ile Asn Asn Gln Val Gly Phe Thr Thr Ser Asn		
	385	390	395
			400

## EP 0 952 221 A2

Pro Lys Asp Ala Arg Ser Thr Pro Tyr Cys Thr Asp Ile Gly Lys Met  
 405 410 415  
 Val Leu Ala Pro Ile Phe His Val Asn Ala Asp Asp Pro Glu Ala Val  
 5 420 425 430  
 Ala Phe Val Thr Arg Leu Ala Leu Asp Tyr Arg Asn Thr Phe Lys Arg  
 435 440 445  
 Asp Val Phe Ile Asp Leu Val Cys Tyr Arg Arg His Gly His Asn Glu  
 10 450 455 460  
 Ala Asp Glu Pro Ser Ala Thr Gln Pro Leu Met Tyr Gln Lys Ile Lys  
 465 470 475 480  
 Lys His Pro Thr Pro Arg Lys Ile Tyr Ala Asp Arg Leu Glu Gly Glu  
 15 485 490 495  
 Gly Val Ala Ser Gln Glu Asp Ala Thr Glu Met Val Asn Leu Tyr Arg  
 500 505 510  
 Asp Ala Leu Asp Ala Gly Glu Cys Val Val Pro Glu Trp Arg Pro Met  
 20 515 520 525  
 Ser Leu His Ser Phe Thr Trp Ser Pro Tyr Leu Asn His Glu Trp Asp  
 530 535 540  
 Glu Pro Tyr Pro Ala Gln Val Asp Met Lys Arg Leu Lys Glu Leu Ala  
 25 545 550 555 560  
 Leu Arg Ile Ser Gln Val Pro Glu Gln Ile Glu Val Gln Ser Arg Val  
 565 570 575  
 Ala Lys Ile Tyr Asn Asp Arg Lys Leu Met Ala Glu Gly Glu Lys Ala  
 30 580 585 590  
 Phe Asp Trp Gly Gly Ala Glu Asn Leu Ala Tyr Ala Thr Leu Val Asp  
 595 600 605  
 Glu Gly Ile Pro Val Arg Leu Ser Gly Glu Asp Ser Gly Arg Gly Thr  
 610 615 620  
 Phe Phe His Arg His Ala Val Val His Asn Gln Ala Asn Gly Ser Thr  
 35 625 630 635 640  
 Tyr Thr Pro Leu His His Ile His Asn Ser Gln Gly Glu Phe Lys Val  
 645 650 655  
 Trp Asp Ser Val Leu Ser Glu Glu Ala Val Leu Ala Phe Glu Tyr Gly  
 40 660 665 670  
 Tyr Ala Thr Ala Glu Pro Arg Val Leu Thr Ile Trp Glu Ala Gln Phe  
 675 680 685  
 Gly Asp Phe Ala Asn Gly Ala Gln Val Val Ile Asp Gln Phe Ile Ser  
 45 690 695 700  
 Ser Gly Glu Gln Lys Trp Gly Arg Met Cys Gly Leu Val Met Leu Leu  
 705 710 715 720  
 Pro His Gly Tyr Glu Gly Gln Gly Pro Glu His Ser Ser Ala Arg Leu  
 50 725 730 735  
 Glu Arg Tyr Leu Gln Leu Cys Ala Glu Gln Asn Met Gln Val Cys Val  
 740 745 750  
 Pro Ser Thr Pro Ala Gln Val Tyr His Met Leu Arg Arg Gln Ala Leu  
 55 755 760 765  
 Arg Gly Met Arg Arg Pro Leu Val Val Met Ser Pro Lys Ser Leu Leu

## EP 0 952 221 A2

770                    775                    780  
 Arg His Pro Leu Ala Ile Ser Ser Leu Asp Glu Leu Ala Asn Gly Ser  
 785                    790                    795                    800  
 5                    Phe Gln Pro Ala Ile Gly Glu Ile Asp Asp Leu Asp Pro Gln Gly Val  
 805                    810                    815  
 Lys Arg Val Val Leu Cys Ser Gly Lys Val Tyr Tyr Asp Leu Leu Glu  
 820                    825                    830  
 10                    Gln Arg Arg Lys Asp Glu Lys Thr Asp Val Ala Ile Val Arg Ile Glu  
 835                    840                    845  
 Gln Leu Tyr Pro Phe Pro His Gln Ala Val Gln Glu Ala Leu Lys Ala  
 850                    855                    860  
 15                    Tyr Ser His Val Gln Asp Phe Val Trp Cys Gln Glu Glu Pro Leu Asn  
 865                    870                    875                    880  
 Gln Gly Ala Trp Tyr Cys Ser Gln His His Phe Arg Asp Val Val Pro  
 885                    890                    895  
 20                    Phe Gly Ala Thr Leu Arg Tyr Ala Gly Arg Pro Ala Ser Ala Ser Pro  
 900                    905                    910  
 Ala Val Gly Tyr Met Ser Val His Gln Gln Gln Gln Asp Leu Val  
 915                    920                    925  
 25                    Asn Asp Ala Leu Asn Val Asn  
 930                    935  
  
 <210> 4  
 <211> 407  
 30                    <212> PRT  
 <213> Enterobacter agglomerans  
 <400> 4  
 Met Ser Ser Val Asp Ile Leu Val Pro Asp Leu Pro Glu Ser Val Ala  
 1                    5                    10                    15  
 35                    Asp Ala Thr Val Ala Thr Trp His Lys Lys Pro Gly Asp Ala Val Ser  
 20                    25                    30  
 Arg Asp Glu Val Ile Val Glu Ile Glu Thr Asp Lys Val Val Leu Glu  
 35                    40                    45  
 40                    Val Pro Ala Ser Ala Asp Gly Val Leu Glu Ala Val Leu Glu Asp Glu  
 50                    55                    60  
 Gly Ala Thr Val Thr Ser Arg Gln Ile Leu Gly Arg Leu Lys Glu Gly  
 65                    70                    75                    80  
 45                    Asn Ser Ala Gly Lys Glu Ser Ser Ala Lys Ala Glu Ser Asn Asp Thr  
 85                    90                    95  
 Thr Pro Ala Gln Arg Gln Thr Ala Ser Leu Glu Glu Ser Ser Asp  
 100                    105                    110  
 50                    Ala Leu Ser Pro Ala Ile Arg Arg Leu Ile Ala Glu His Asn Leu Asp  
 115                    120                    125  
 Ala Ala Gln Ile Lys Gly Thr Gly Val Gly Gly Arg Leu Thr Arg Glu  
 130                    135                    140  
 55                    Asp Val Glu Lys His Leu Ala Asn Lys Pro Gln Ala Glu Lys Ala Ala  
 145                    150                    155                    160

## EP 0 952 221 A2

Ala Pro Ala Ala Gly Ala Ala Thr Ala Gln Gln Pro Val Ala Asn Arg  
 165 170 175  
 Ser Glu Lys Arg Val Pro Met Thr Arg Leu Arg Lys Arg Val Ala Glu  
 5 180 185 190  
 Arg Leu Leu Glu Ala Lys Asn Ser Thr Ala Met Leu Thr Thr Phe Asn  
 195 200 205  
 Glu Ile Asn Met Lys Pro Ile Met Asp Leu Arg Lys Gln Tyr Gly Asp  
 10 210 215 220  
 Ala Phe Glu Lys Arg His Gly Val Arg Leu Gly Phe Met Ser Phe Tyr  
 225 230 235 240  
 Ile Lys Ala Val Val Glu Ala Leu Lys Arg Tyr Pro Glu Val Asn Ala  
 15 245 250 255  
 Ser Ile Asp Gly Glu Asp Val Val Tyr His Asn Tyr Phe Asp Val Ser  
 260 265 270  
 Ile Ala Val Ser Thr Pro Arg Gly Leu Val Thr Pro Val Leu Arg Asp  
 20 275 280 285  
 Val Asp Ala Leu Ser Met Ala Asp Ile Glu Lys Lys Ile Lys Glu Leu  
 290 295 300  
 Ala Val Lys Gly Arg Asp Gly Lys Leu Thr Val Asp Asp Leu Thr Gly  
 25 305 310 315 320  
 Gly Asn Phe Thr Ile Thr Asn Gly Gly Val Phe Gly Ser Leu Met Ser  
 325 330 335  
 Thr Pro Ile Ile Asn Pro Pro Gln Ser Ala Ile Leu Gly Met His Ala  
 340 345 350  
 Ile Lys Asp Arg Pro Met Ala Val Asn Gly Gln Val Val Ile Leu Pro  
 30 355 360 365  
 Met Met Tyr Leu Ala Leu Ser Tyr Asp His Arg Leu Ile Asp Gly Arg  
 370 375 380  
 Glu Ser Val Gly Tyr Leu Val Ala Val Lys Glu Met Leu Glu Asp Pro  
 35 385 390 395 400  
 Ala Arg Leu Leu Leu Asp Val  
 405  
 40 <210> 5  
 <211> 40  
 <212> PRT  
 <213> Enterobacter agglomerans  
 45 <400> 5  
 Met Asn Leu His Glu Tyr Gln Ala Lys Gln Leu Phe Ala Arg Tyr Gly  
 1 5 10 15  
 Met Pro Ala Pro Thr Gly Tyr Ala Cys Thr Thr Pro Arg Glu Ala Glu  
 50 20 25 30  
 Glu Ala Ala Ser Lys Ile Gly Ala  
 35 40  
 55 <210> 6  
 <211> 30

```
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer
<400> 6
gtcgcacaata gccygaatct gttctggtcg 30

<210> 7
<211> 30
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer
<400> 7
aagcttatcg acgctccctt cccccaccgtt 30
```

25 Claims

- 30 1. A microorganism belonging to the genus *Enterobacter* or *Serratia* having the ability to produce L-glutamic acid and having at least one of the following properties:

35 (a) the microorganism has increased activity of an enzyme catalyzing a reaction in the L-glutamic acid biosynthesis; and  
(b) the microorganism has decreased acitivity or is deficient in an activity of an enzyme catalyzing a reaction branching from the pathway of the L-glutamic acid biosynthesis and producing a compound other than L-glutamic acid.

40 2. A microorganism according to claim 1 wherein the enzyme catalyzing the reaction in the L-glutamic acid biosynthesis is at least one selected from the group consisting of citrate synthase, phosphoenolpyruvate carboxylase, and glutamate dehydrogenase.

45 3. A microorganism according to claim 2 wherein the enzyme catalyzing the reaction in the L-glutamic acid biosynthesis includes all of citrate synthase, phosphoenolpyruvate carboxylase, and glutamate dehydrogenase.

4. A microorganism according to any one of claims 1 to 3 wherein the enzyme catalyzing the reaction branching from the pathway of the L-glutamic acid biosynthesis and producing a compound other than L-glutamic acid is  $\alpha$ -ketoglutarate dehydrogenase.

5. A microorganism according to any one of claims 1 to 4 which is *Enterobacter agglomerans* or *Serratia liquefaciens*.

50 6. A method for producing L-glutamic acid which comprises culturing the microorganism as defined in any one of claims 1 to 5 in a liquid culture medium to produce and accumulate L-glutamic acid in the culture medium, and collecting the L-glutamic acid from the culture medium.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6

[88.0% / 935 aa]

1' MQNSAMKPWLDSWLAGANQSYIEQLYEDFLTDPDSVAVWRSMFQQLPGTGVKPEQFHS  
 1" MQNSALKWLDSYLSGANQSWIEQLYEDFLTDPDSVADANWRSTFQQLPGTGVKPDQFHS  
 61' ATREYFRRLAKDASRYTSSVTDPATNSKQVKVLQLINAFRFRGHQEANLDPLGLWYKQDRV  
 61" QTREYFRRLAKDASRYSSTISDPDTNVQVKVLQLINAAYRFRGHQHANLDPLGLWYQQDKV  
 121' ADLDPAFHDLTADLFQESFNVGSFAIGKETMKLADLFALKQTYCGSIGAEMYHINNT  
 121" ADLDPFSHDLTEADFQETFNVGSFASGKETMKLGELLEALKQTYCGPIGAEMYHIT  
 181' KRWIQQRIESGASQTFSFGEKKGFLKELTAAEGLKYLGAKFPGAKRFSLEGGDALVPM  
 181" KRWIQQRIESG--RATFNSEEKKRFLSELTAEGLERYLGAKFPGAKRFSLEGGDALIPM  
 241' LREMIRHAGKSSTREVVLQMAHRGRNLNVLINVLGKPKQDLFDEFSGKHKEHLGTGDVKYH  
 239" LKEMIRHAGNSSTREVVLQMAHRGRNLNVNLGKPKQDLFDEFAGKHKEHLGTGDVKYH  
 301' MGFSSDIETEGGLVHLALAFNPSHLEIVSPVVMGSVRARLDRLAEPVSNKVLPIIHGDA  
 299" MGFSSDFQTDGGLVHLALAFNPSHLEIVSPVIGSVRARLDRLEPSSNKVLPIIHGDA  
 361' AVIGQQVWQETLNMSQARGYEVCGTWRIVINNNQVGFTTSNPKDARSTPYCTDIGKMWAP  
 359" AVTQQGVWQETLNMSKARGYEVCGTWRIVINNNQVGFTTSNPLDARSTPYCTDIGKMWQAP  
 421' IFHVNADDPEAVAFVTRLALDYLRTFKRDVFIDLVCYRRGHNEADEPSATQPLMYQKIK  
 419" IFHVNADDPEAVAFVTRLALDFRNTFKRDVFIDLVSYRRGHNEADEPSATQPLMYQKIK  
 481' KHPPTRKIYADRLEGEVASQEDATEMVNLRYDALDAGECVVPEWRPMSLHSFTWSPYLN  
 479" KHPPTRKIYADKLEQEKVATLDATEMVNLRYDALDAGDCVVAEWRPMNMHSFTWSPYLN  
 541' HEWDEPYPAQVDMKRLKELALRISQVPEQIEVQSRVAKIYNDRKLMAEGEKAFDWGAEN  
 539" HEWDEEYPNKVEMKRLQELAKRISTVPEAVEMQSRVAKIYGDRQAMAAGEKLFDWGAEN  
 601' LAYATLVDEGIPVRLSGEDSGRTFFFHRHAWVHNQANGSTYTPLHHIHNSQGEFKVWDSV  
 599" LAYATLVDEGIPVRLSGEDSGRTFFFHRHAWIHNQNSNGSTYTPLQHIIHNGQGAFRVWDSV  
 661' LSEEAVLAFEGYGYATAEPRLTIWEAQFGDFANGAQVVIDQFISSEQKNGRMCGLVMLL  
 659" LSEEAVLAFEGYGYATAEPRTLTIWEAQFGDFANGAQVVIDQFISSEQKNGRMCGLVMLL  
 721' PHGYEGQQPEHSSARLERYLQLCAEQNMQVCPSTPAQVYHMLRRQALRGMRPPLVVMSP  
 719" PHGYEGQQPEHSSARLERYLQLCAEQNMQVCPSTPAQVYHMLRRQALRGMRPPLVVMSP  
 781' KSLLRHPLAISLDELANGSFQPAIGEIDLDLDPQGVKRVWLCGKVVYDLLEQRRKDEKT  
 779" KSLLRHPLAVSSEELANGTFLPAIGEIDEQLPKGVKRVWMCQKVVYDLLEQRRKNNQH  
 841' DVAIVRIEQLYPFPHQAVQEALKAYSHVQDFVWCQEEPLNQGAWYCSQHHFRDVPFGAT  
 839" DVAIVRIEQLYPFPHQAMQEVLQQFAHVKDPMQEEPLNQGAWYCSQHHFREVIPFGAS  
 901' LRYAGRSPASAPAVGYMSVHQQQQQDLVNDALNV  
 899" LRYAGRSPASAPAVGYMSVHQKQQQDLVNDALNVE

EP 0 952 221 A2

[88.2% / 407 aa]

1' MS SVDILVPDLPESVADATVATWHKKPGDAVS RDEVIVEIETDKV L E V P A S A D G V / L E A V  
1" MS SVDILVPDLPESVADATVATWHKKPGDAV RDEV L V E I E T D K V L E V P A S A D G I L D A V  
61' LEDEGATVTSRQILGRLKEGNSAGKESSAKAESNDTPAQRQTASLEEESDALSPAIRR  
61" LEDEGTTVTSRQILGRLREGNSAGKESETAKSEEKASTPAQRQQASLEEQNNDALSPAIRR  
121' LIAEHNLDAAQIKGTGVGGRLTREDVEKHLANKPQAEEAAAPAAAGAATAQQPVANRSEKR  
121" LLAEHNLDAASAIKGTGVGGRLTREDVEKHLAKAPAKE--SAPAAAAPAAQPALAARSEKR  
181' VPMTRLRKRAERLLEAKNSTAMLTTFNEINNMKPIMDLRKQYGAFFKRHGVR LGFMSFY  
179" VPMTRLRKRAERLLEAKNSTAMLTTFNEVNMKPIMDLRKQYGEAFFKRHGIRLGFMFSFY  
241' IKAVVEALKRYPEVNASIDGEDVYHNYFDV SIAVSTPRGLVTPVLRDV D A L S M A D I E K K  
239" VKAVVEALKRYPEVNASIDGDDVYHNYFDV S M A V S T P R G L V T P V L R D V D T L G M A D I E K K  
301' IKELAVKGRDGKLT V D D L T G G N F T I T N G G V F G S L M S T P I I N P P Q S A I L G M H A I K D R P M A V  
299" IKELAVKGRDGKLT V E D L T G G N F T I T N G G V F G S L M S T P I I N P P Q S A I L G M H A I K D R P M A V  
361' NGQV V I L P M M Y L A L S Y D H R L I D G R E S V G Y L V A V K E M L E D P A R L L L D V  
359" NGQV E I L P M M Y L A L S Y D H R L I D G R E S V G F L V T I K E L L E D P T R L L L D V

FIG. 8

[95.1% / 41 aa]

1' MNLHEYQAKQLFARYGMPAPTGYACTTPREAEAAASKIGAG  
1" MNLHEYQAKQLFARYGLPAPVGYACTTPREAEAAASKIGAGPWWKCQVHAGGRGKAGGV

FIG. 9

[97.4% / 39 aa]

1' AFSVFRCHSIMNCVSVC PKGLNPTRAIGHIKSMLLQRSA  
181" FLIDSRDTETDSRLDGLSDAFSVFRCHSIMNCVSVC PKGLNPTRAIGHIKSMLLQRNA

FIG. 10



(19) Europäisches Patentamt

European Patent Office

Offic europ en des brevets



(11) EP 0 952 221 A3

(12) EUROPEAN PATENT APPLICATION

(88) Date of publication A3:  
12.09.2001 Bulletin 2001/37

(51) Int Cl. 7: C12N 15/53, C12N 15/60,  
C12N 1/21, C12N 1/20,  
C12P 13/14  
//(C12N1/20, C12R1:01, 1:425)

(43) Date of publication A2:  
27.10.1999 Bulletin 1999/43

(21) Application number: 99105508.8

(22) Date of filing: 17.03.1999

(84) Designated Contracting States:  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE  
Designated Extension States:  
AL LT LV MK RO SI

(30) Priority: 18.03.1998 JP 6906898  
19.10.1998 JP 29712998

(71) Applicant: Ajinomoto Co., Inc.  
Tokyo (JP)

(72) Inventors:  
• Izui, Hiroshi c/o Ajinomoto Co., Inc.  
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)

- Ono, Eiji c/o Ajinomoto Co., Inc.  
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)
- Matsui, Kazuhiko c/o Ajinomoto Co., Inc.  
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)
- Moriya, Mika c/o Ajinomoto Co., Inc.  
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)
- Ito, Hisao c/o Ajinomoto Co., Inc.  
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)
- Hara, Yoshihiko c/o Ajinomoto Co., Inc.  
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)

(74) Representative: Strehl Schübel-Hopf & Partner  
Maximilianstrasse 54  
80538 München (DE)

(54) L-glutamic acid-producing bacterium and method for producing L-glutamic acid

(57) L-Glutamic acid is produced by culturing in a liquid culture medium a microorganism belonging to the genus *Enterobacter* or *Serratia* and having an ability to produce L-glutamic acid, which increases in an activity of enzyme catalyzing a reaction for L-glutamic acid bio-

synthesis, or which decreases in or is deficient in an activity of an enzyme catalyzing a reaction branching from a pathway for L-glutamic acid biosynthesis and producing a compound other than L-glutamic acid, and collecting produced L-glutamic acid from the culture medium.



## EUROPEAN SEARCH REPORT

Application Number  
EP 99 10 5508

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X, D	EP 0 670 370 A (AJINOMOTO KK) 6 September 1995 (1995-09-06) * the whole document *	1,2,4,6	C12N15/53 C12N15/60 C12N1/21 C12N1/20 C12P13/14 //(C12N1/20, C12R1:01, 1:425)
X	WO 97 08294 A (AJINOMOTO KK ;MATSUI KAZUHIKO (JP); HUKASE KUMIKO (JP); TSUJIMOTO) 6 March 1997 (1997-03-06) * the whole document *	1,2,4,6	
E	EP 1 078 989 A (AJINOMOTO KK) 28 February 2001 (2001-02-28) * the whole document *	1-6	
TECHNICAL FIELDS SEARCHED (Int.Cl.6)			
C12N C12P			
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	20 July 2001	Oderwald, H	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.

EP 99 10 5508

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20-07-2001

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
EP 0670370	A	06-09-1995	JP	7203980 A	08-08-1995
			BR	9500052 A	03-10-1995
			CN	1128295 A	07-08-1996
			US	5573945 A	12-11-1996
WO 9708294	A	06-03-1997	BR	9610016 A	06-07-1999
			CN	1193343 A	16-09-1998
			DE	19681532 T	03-12-1998
			FR	2738014 A	28-02-1997
			US	6110714 A	29-08-2000
EP 1078989	A	28-02-2001	AU	5345200 A	22-02-2001
			BR	0003695 A	05-06-2001
			CN	1292421 A	25-04-2001
			PL	341974 A	26-02-2001